|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dopazo C, Søreide K, Rangelova E, Mieog S,
Carrion-Alvarez L, Diaz-Nieto R, Primavesi F and Stättner S:
Hepatocellular carcinoma. Eur J Surg Oncol. 50:1073132024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Rourke JM, Sagar VM, Shah T and Shetty
S: Carcinogenesis on the background of liver fibrosis: Implications
for the management of hepatocellular cancer. World J Gastroenterol.
24:4436–4447. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barry AE, Baldeosingh R, Lamm R, Patel K,
Zhang K, Dominguez DA, Kirton KJ, Shah AP and Dang H: Hepatic
stellate cells and hepatocarcinogenesis. Front Cell Dev Biol.
8:7092020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen SL and Morgan TR: The natural history
of hepatitis C virus (HCV) infection. Int J Med Sci. 3:47–52. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta S, Read SA, Shackel NA, Hebbard L,
George J and Ahlenstiel G: The role of micronutrients in the
infection and subsequent response to hepatitis c virus. Cells.
8:6032019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Kang R, Kroemer G and Tang D:
Broadening horizons: The role of ferroptosis in cancer. Nat Rev
Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Li J, Kang R, Klionsky DJ and Tang
D: Ferroptosis: Machinery and regulation. Autophagy. 17:2054–2081.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dixon SJ and Olzmann JA: The cell biology
of ferroptosis. Nat Rev Mol Cell Biol. 25:424–42. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng F, Nijiati S, Tang L, Ye J, Zhou Z
and Chen X: Ferroptosis detection: From approaches to applications.
Angew Chem Int Ed Engl. 62:e2023003792023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He T and Ling F: CALCR knockdown inhibits
the development and progression of non-small-cell lung cancer.
Carcinogenesis. 42:1390–1398. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue C, Gu X and Li L: Immune
classifier-based signatures provide good prognostic stratification
and predict the clinical benefits of immune-based therapies for
hepatocellular carcinoma. Cancer Cell Int. 21:4712021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masi L and Brandi ML: Calcitonin and
calcitonin receptors. Clin Cases Miner Bone Metab. 4:117–122.
2007.PubMed/NCBI
|
|
16
|
Mitra P, Guha M, Ghosh S, Mukherjee S,
Bankura B, Pal DK, Maity B and Das M: Association of calcitonin
receptor gene (CALCR) polymorphism with kidney stone disease in the
population of West Bengal, India. Gene. 622:23–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nugent A and Proia RL: The role of G
protein-coupled receptors in lymphoid malignancies. Cell Signal.
39:95–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan H, Xing Z, Liu S, Gao P, Wang Q and
Guo G: CALCR exacerbates renal cell carcinoma progression via
stabilizing CD44. Aging (Albany NY). 16:10765–10783. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
20
|
GTEx Consortium: The genotype-tissue
expression (GTEx) project. Nat Genet. 45:580–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoshida Y, Brunet JP, Tamayo P, Golub TR
and Mesirov JP: Subclass mapping: Identifying common subtypes in
independent disease data sets. PLoS One. 2:e11952007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–428. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herzog BH, Baer JM, Borcherding N,
Kingston NL, Belle JI, Knolhoff BL, Hogg GD, Ahmad F, Kang V,
Petrone J, et al: Tumor-associated fibrosis impairs immune
surveillance and response to immune checkpoint blockade in
non-small cell lung cancer. Sci Transl Med. 15:eadh80052023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu X, Zhou J, Wu H, Chen S, Zhang L, Tang
W, Duan L, Wang Y, McCabe E, Hu M, et al: Fibrotic immune
microenvironment remodeling mediates superior anti-tumor efficacy
of a nano-PD-L1 trap in hepatocellular carcinoma. Mol Ther.
31:119–133. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mancinelli R, Ceci L, Kennedy L, Francis
H, Meadows V, Chen L, Carpino G, Kyritsi K, Wu K, Zhou T, et al:
The effects of taurocholic acid on biliary damage and liver
fibrosis are mediated by calcitonin-gene-related peptide signaling.
Cells. 11:15912022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Röhrich M, Leitz D, Glatting FM, Wefers
AK, Weinheimer O, Flechsig P, Kahn N, Mall MA, Giesel FL,
Kratochwil C, et al: Fibroblast activation protein-specific PET/CT
imaging in fibrotic interstitial lung diseases and lung cancer: A
translational exploratory study. J Nucl Med. 63:127–133. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castellani C, Malerba G, Sangalli A,
Delmarco A, Petrelli E, Rossini M, Assael BM and Mottes M: The
genetic background of osteoporosis in cystic fibrosis: Association
analysis with polymorphic markers in four candidate genes. J Cyst
Fibros. 5:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhattacharjee S, Hamberger F, Ravichandra
A, Miller M, Nair A, Affo S, Filliol A, Chin L, Savage V, Yin D, et
al: Tumor restriction by type I collagen opposes tumor-promoting
effects of cancer-associated fibroblasts. J Clin Invest.
131:e1469872021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moreira LM, Takawale A, Hulsurkar M,
Menassa DA, Antanaviciute A, Lahiri SK, Mehta N, Evans N, Psarros
C, Robinson P, et al: Paracrine signaling by cardiac calcitonin
controls atrial fibrogenesis and arrhythmia. Nature. 587:460–465.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chida K, Oshi M, Roy AM, Yachi T, Nara M,
Yamada K, Matsuura O, Hashizume O, Endo I and Takabe K: E2F target
score is associated with cell proliferation and survival of
patients with hepatocellular carcinoma. Surgery. 174:307–314. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oshi M, Patel A, Le L, Tokumaru Y, Yan L,
Matsuyama R, Endo I and Takabe K: G2M checkpoint pathway alone is
associated with drug response and survival among cell
proliferation-related pathways in pancreatic cancer. Am J Cancer
Res. 11:3070–3084. 2021.PubMed/NCBI
|
|
34
|
Xu G and Jiang D: The role and mechanism
of exogenous calcitonin gene-related peptide on mesenchymal stem
cell proliferation and osteogenetic formation. Cell Biochem
Biophys. 69:369–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chiang JYL and Ferrell JM: Bile acid
metabolism in liver pathobiology. Gene Expr. 18:71–87. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RV Jr: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bin X, Luo Z, Wang J and Zhou S:
Identification of a five immune term signature for prognosis and
therapy options (immunotherapy versus targeted therapy) for
patients with hepatocellular carcinoma. Comput Math Methods Med.
2:89589622023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Addeo A, Friedlaender A, Banna GL and
Weiss GJ: TMB or not TMB as a biomarker: That is the question. Crit
Rev Oncol Hematol. 163:1033742021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Halford SE, Sawyer EJ, Lambros MB, Gorman
P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM,
Akslen LA, et al: MSI-low, a real phenomenon which varies in
frequency among cancer types. J Pathol. 201:389–394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jardim DL, Goodman A, de Melo Gagliato D
and Kurzrock R: The challenges of tumor mutational burden as an
immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Akinjiyan FA, Morecroft R, Phillipps J,
Adeyelu T, Elliott A, Park SJ, Butt OH, Zhou AY and Ansstas G:
Homologous recombination deficiency (HRD) in cutaneous oncology.
Int J Mol Sci. 24:107712023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
García-Solano J, Turpin-Sevilla MDC,
García-García F, Carbonell-Muñoz R, Torres-Moreno D, Conesa A and
Conesa-Zamora P: Differences in gene expression profiling and
biomarkers between histological colorectal carcinoma subsets from
the serrated pathway. Histopathology. 75:496–507. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rui R, Zhou L and He S: Cancer
immunotherapies: Advances and bottlenecks. Front Immunol.
14:12124762023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang D, Zhang X, Liu Z, Han T, Zhao K, Xu
X, Zhang X, Ren X and Qin C: An integrative multi-omics analysis
based on disulfidptosis-related prognostic signature and distinct
subtypes of clear cell renal cell carcinoma. Front Oncol.
13:12070682023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumor purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio YY, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in non-small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
